---
title: "Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295360680.md"
description: "Genmab (GMAB) announced its Phase 3 trial of epcoritamab plus lenalidomide met the primary endpoint, significantly improving progression-free survival in relapsed/refractory DLBCL. The company highlighted 2026 growth drivers, including increased royalties from DARZALEX and Kesimpta, rising sales of EPKINLY/TEPKINLY, and higher amortization costs. Additionally, Guggenheim raised GMAB's price target to $42 with a Buy rating, citing an improved valuation outlook."
datetime: "2026-08-10T05:15:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295360680.md)
  - [en](https://longbridge.com/en/news/295360680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295360680.md)
generator: "portal-rs"
---

# Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise

Genmab A/S Sponsored ADR (OMXCOP:GMAB) saw a Phase 3 win as epcoritamab+lenalidomide improved progression‑free survival in relapsed/refractory DLBCL, while 2026 drivers — higher DARZALEX/Kesimpta royalties, rising EPKINLY/TEPKINLY sales and increased amortization/costs — and Guggenheim’s $42 price target lift the outlook.

**Previous Week Recap**

-   **GMAB Phase 3 Combo Hits Primary Endpoint**: GMAB: Phase 3 combo of epcoritamab + lenalidomide in relapsed/refractory DLBCL met primary endpoint, showing statistically significant improvement in progression‑free survival versus control. GlobeNewswire
-   **GMAB 2026 Drivers Include Royalties, Net Sales**: GMAB reports 2026 drivers: higher DARZALEX and Kesimpta royalties, rising EPKINLY/TEPKINLY net sales, increased amortization and costs, and ongoing pipeline and commercialization investments. Dow Jones Newswires
-   **Guggenheim Raises GMAB Target To $42**: Guggenheim raised Genmab A/S Sponsored ADR (GMAB) price target to $42 from $40 and kept a Buy rating, citing an updated valuation outlook. Dow Jones Newswires

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [GMAB: Late-stage pipeline advances and strong financials set up multiple key data readouts in Q4](https://longbridge.com/en/news/299058356.md)
- [Genmab Updates Articles of Association, Preserves Broad Capital-Raising Powers](https://longbridge.com/en/news/298480228.md)
- [Genmab Calls October Extraordinary General Meeting to Address Board Remuneration and Shareholder Outreach](https://longbridge.com/en/news/298318223.md)
- [Genmab announces extraordinary general meeting](https://longbridge.com/en/news/298297397.md)
- [Capital Increase in Genmab as a Result of Employee Warrant Exercise](https://longbridge.com/en/news/298355377.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**